Cellectis S.A. (CLLS) Stock Score, Valuation & Financial Research
Cellectis S.A. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 17/100.
Quick answer for CLLS
Cellectis S.A. currently has a Wall Street Score of 17/100. The stored market price is $1.82. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is +1.5 points. These figures are a research snapshot, not a buy or sell recommendation.
What Cellectis S.A. does
Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells. Its operations are divided into two distinct divisions: Therapeutics and Plants. The therapeutic pipeline includes several product candidates currently undergoing development. Among these is UCART19, an allogeneic T-cell therapy targeting CD19-expressing blood cancers such as acute lymphoblastic leukemia. Other key developments encompass ALLO-501 and ALLO-501A, designed for diffuse large B-cell lymphoma and follicular lymphoma in relapsed or refractory patients; ALLO-316, intended for Renal Cell Carcinoma; UCART123 for acute myeloid leukemia; and UCART22 for B-cell acute lymphoblastic leukemia. Furth
CLLS financial snapshot
- Wall Street Score:
- 17/100
- Current price:
- $1.82
- Market capitalization:
- $182.8M
- Revenue:
- $56.6M
- Net income:
- $-65.3M
- Free cash flow:
- $-42.5M
- Cash:
- $35.6M
- Total debt:
- $84.6M
- EPS:
- -0.66
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 23/100
What stands out
- Reported year-over-year revenue growth is -0.2%.
- Free cash flow is $-42.5M, showing cash burn in the current stored period.
- The balance sheet shows $35.6M of cash versus $84.6M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +1.5 points: CLLS increased 1.5 points because Asset improved by 13.9 points, Buffett improved by 2.3 points.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-14.
How to research CLLS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.